CT-guided Radioactive I-125 Seeds Implantation for Early Stage Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03916367|
Recruitment Status : Completed
First Posted : April 16, 2019
Last Update Posted : May 21, 2019
|Condition or disease||Intervention/treatment|
|Early Stage Non-small Cell Lung Cancer||Radiation: CT-guided Radioactive I-125 Seeds Implantation|
|Study Type :||Observational|
|Actual Enrollment :||39 participants|
|Official Title:||Clinical Outcome of CT-guided Radioactive Iodine-125 Seeds Implantation for Inoperable Early Stage Non-small Cell Lung Cancer|
|Actual Study Start Date :||December 15, 2010|
|Actual Primary Completion Date :||December 15, 2018|
|Actual Study Completion Date :||February 15, 2019|
Early Stage Lung Cancer
The patients with early stage non-small cell lung cancer who were treated with CT-guided radioactive iodine-125 seeds implantation during December 2010 to December 2018.
Radiation: CT-guided Radioactive I-125 Seeds Implantation
The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring.
- Local control time [ Time Frame: Outcomes were followed up every 3 months after enrollment. The last follow-up timepoint is February 2019. ]The time from the date of seeds implantation to the date of recurrence of the implanted tumor or the date of last observation.
- Overall survival time [ Time Frame: Outcomes were followed up every 3 months after enrollment. The last follow-up timepoint is February 2019. ]The time from the date of seeds implantation to the date of death from any cause or the date of last observation.
- Incidence of adverse events [ Time Frame: Outcomes were followed up every 3 months after seeds implantation. The last follow-up timepoint is February 2019. ]The adverse events were evaluated by the common terminology criteria for adverse events (CTCAE). The rate of each adverse event was measured.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03916367
|Principal Investigator:||Junjie Wang, M.D. Ph.D.||Department of Radiation Oncology, Peking University Third Hospital|